Bellemore S M, Nikoopour E, Krougly O, Lee-Chan E, Fouser L A, Singh B
Centre for Human Immunology and Department of Microbiology and Immunology and Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Inflammation and Immunology, Biotherapeutics Research and Development, Pfizer Inc., Cambridge, MA, 02140, USA.
Clin Exp Immunol. 2016 Mar;183(3):380-8. doi: 10.1111/cei.12735. Epub 2015 Dec 3.
We have shown that pathogenic T helper type 17 (Th17) cells differentiated from naive CD4(+) T cells of BDC2·5 T cell receptor transgenic non-obese diabetic (NOD) mice by interleukin (IL)-23 plus IL-6 produce IL-17, IL-22 and induce type 1 diabetes (T1D). Neutralizing interferon (IFN)-γ during the polarization process leads to a significant increase in IL-22 production by these Th17 cells. We also isolated IL-22-producing Th17 cells from the pancreas of wild-type diabetic NOD mice. IL-27 also blocked IL-22 production from diabetogenic Th17 cells. To determine the functional role of IL-22 produced by pathogenic Th17 cells in T1D we neutralized IL-22 in vivo by using anti-IL-22 monoclonal antibody. We found that blocking IL-22 did not alter significantly adoptive transfer of disease by pathogenic Th17 cells. Therefore, IL-22 is not required for T1D pathogenesis. The IL-22Rα receptor for IL-22 however, increased in the pancreas of NOD mice during disease progression and based upon our and other studies we suggest that IL-22 may have a regenerative and protective role in the pancreatic islets.
我们已经证明,由白细胞介素(IL)-23加IL-6诱导分化自BDC2·5 T细胞受体转基因非肥胖糖尿病(NOD)小鼠的初始CD4(+) T细胞的致病性1型辅助性T细胞(Th17)可产生IL-17、IL-22,并引发1型糖尿病(T1D)。在极化过程中中和干扰素(IFN)-γ会导致这些Th17细胞产生的IL-22显著增加。我们还从野生型糖尿病NOD小鼠的胰腺中分离出了产生IL-22的Th17细胞。IL-27也可阻断致糖尿病性Th17细胞产生IL-22。为了确定致病性Th17细胞产生的IL-22在T1D中的功能作用,我们通过使用抗IL-22单克隆抗体在体内中和IL-22。我们发现阻断IL-22不会显著改变致病性Th17细胞介导的疾病过继转移。因此,T1D发病机制并不需要IL-22。然而,IL-22的受体IL-22Rα在NOD小鼠疾病进展过程中胰腺中表达增加,基于我们和其他研究,我们认为IL-22可能在胰岛中具有再生和保护作用。